MuReva Phototherapy

10:45 AM - 11:00 AM, Wednesday, June 5, 2019 ・ Theater 4
MuReva Phototherapy develops uniquely safe, patient-friendly and clinically proven devices to treat oral toxicities from cancer therapy. Our flagship product targets Oral Mucositis (OM), one of the most common and debilitating side effects of cancer therapy. OM is an extremely painful condition characterized by inflammation and ulceration of the oral mucosa. Current management approaches lack clinical evidence of success and no current preventive therapies are effective and practical. A new form of treatment called Phototherapy or Photobiomodulation therapy utilizes a specific dosage of light (wavelength, power and time) to stimulate wound healing. It has been clinically proven to treat OM, however several barriers to current light delivery methods have prevented its adoption in the US. Our patented device is a patient-friendly mouthpiece capable of delivering high-power light to all OM susceptible soft-tissues simultaneously and can deliver a full-treatment in as little as 5 minutes
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Not Provided.
Company HQ State:
Not Provided.
Company HQ Country:
Not Provided.
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
Not Provided.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.